Restriction endonuclease site maps were constructed for the genome of a caprine adenovirus (GAdV), strain NC90-7261, which was isolated in 1990 from a 3-year-old goat with encephalitis. Genomic GAdV DNA was digested with seven restriction endonucleases (RE). Genomic DNA libraries of GAdV were constructed by cloning BamRl and Hindïíl restriction fragments into a plasmid vector. Using cloned GAdV genomic fragments as probes in Southern blot hybridizations, an RE site map was constructed. The position of several clones was confirmed by limited nucleotide sequencing and the location of several RE sites was determined by single or double RE digestions of cloned fragments. The size of the GAdV genome was determined to be 28.2 kbp. The restriction pattern described in this report is different from that of other adenovimses. Although the genomic organization of this GAdV is likely to be similar to that of other adenoviruses, the overall level of sequence similarity is low.

Keywords:
Caprine adenovirus, Cloning, Restriction mapping
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.